Pharmaceuticals
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)
YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-11-28 09:48
1825
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...
2023-11-28 08:00
1247
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients
HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...
2023-11-27 21:30
1207
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia
- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...
2023-11-24 22:00
3054
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication
SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou,China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the firs...
2023-11-24 19:57
2092
China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation
SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) ofChina has accepted the...
2023-11-24 19:00
2006
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of early iron deficiency diagnosis and treatment and its impact on quality of life ST. GALLEN, SWITZERL...
2023-11-24 15:00
3580
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the ...
2023-11-24 12:54
3495
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-24 08:42
3730
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL...
2023-11-23 16:04
4093
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease) and vessel-related rare disease indications * Unique Tie2-activating antibody program, PMC-403, demonstrates efficacy in improving survival and reducing vascular leak...
2023-11-23 10:31
1258
Ark Biopharmaceutical Receives IND Approval from NMPA for AK0610, a Respiratory Syncytial Virus Neutralizing Antibody
SHANGHAI, Nov. 23, 2023 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announces that it had received IND approval from National Medical Products Administration (NMPA) for a novel antibody drug AK0610. This antibody drug is bioengineered based on a neutralizing antibody origina...
2023-11-23 08:00
1987
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-23 08:00
2927
CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan
First Reimbursed Amyloid PET Diagnostic Tool in Japan TOKYO and BERLIN, Nov. 23, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben18F injection) has been approved from the Ministry of Health, Labor, and ...
2023-11-23 01:00
1610
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale * This end-to-end continuous bioprocess, which is in place for WuXi Biologics global manufacturing network, is...
2023-11-22 13:21
3318
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ot...
2023-11-22 12:40
5705
XtalPi and EDDC Sign New Collaboration, Empowering Biomedical Innovation with Robotics and Large Language Models
SHENZHEN, China, Nov. 22, 2023 /PRNewswire/ -- Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC),Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboratio...
2023-11-22 09:00
1901
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients - ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors...
2023-11-21 20:15
1740
ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop
SEOUL, South Korea, Nov. 20, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapid Preparedness of Pandemic Vaccine in 100 Days using ST Pharm's own mRNA Platform Technology' at the Korea-CEPI R&D Workshop in World Bio Summit 2023, organized by Korea Health Industry Development...
2023-11-21 12:00
1153
Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells in Cancer Prevention, Beauty, and Anti-aging
SUZHOU, China, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in ca...
2023-11-20 20:00
957
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2943
